Has apotex announced a deadline for ruxolitinib's fda submission?

I don’t have a public record in my current data of Apotex announcing a specific deadline for an FDA submission for ruxolitinib. It’s possible there has been new information since my last update, or the announcement could be buried in a press release or investor presentation.

If you’d like, I can help you verify it by:
- Checking Apotex’s official investor relations releases and press statements.
- Looking at FDA regulatory news or the Daily FAX/AndA announcements (if available).
- Searching reliable financial news outlets (Reuters, Bloomberg, etc.) for any coverage.
- Checking the FDA’s Orange Book or the company’s latest regulatory filings for ANDA status and submission timelines.

If you can share a link or date you saw, I can summarize and interpret it. Also, short context: ruxolitinib (Jakafi) is a branded product; any generic submission would depend on patent and exclusivity status, which can influence when an ANDA filing is announced or pursued.